Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 1.00 |
| ▸ | RXRB | P28702 | 11/20 | 1.00 |
| ▸ | RXRG | P48443 | 11/20 | 1.00 |
| ▸ | RARB | P10826 | 6/20 | 0.68 |
| ▸ | RARG | P13631 | 6/20 | 0.68 |
| ▸ | RARA | P10276 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8617082 | 0.88 | RXRA (0.78) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8014387 | 0.88 | RXRA (0.78) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7723496 | 0.86 | RXRA (0.76) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7719786 | 0.84 | RXRA (0.72) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL9867927 | 0.83 | RXRA (0.71) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8015924 | 0.83 | RXRA (0.71) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7720955 | 0.83 | RXRA (0.71) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7719793 | 0.83 | RXRA (0.70) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7716681 | 0.82 | RXRA (0.70) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7760173 | 0.82 | RXRA (0.69) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8066976-B2 | Foaming compositions for hair care | GALDERMA S.A. (CH) | 2011-11-29 | — | — | US | claimed |
| US-20100234337-A1 | FOAMING COMPOSITIONS FOR HAIR CARE | GALDERMA S.A. (CH) | 2010-09-16 | — | — | US | claimed |
| EP-1087747-B1 | FOAMING COMPOSITION FOR HAIR CARE | GALDERMA SA (CH) | 2005-11-09 | — | — | EP | claimed |
| EP-1082111-A4 | ASSAY FOR IDENTIFICATION OF COMPOUNDS THAT PROMOTE MELANIN PRODUCTION AND RETINOID-LIKE COMPOUNDS IDENTIFIED BY SAID ASSAY | GALDERMA RES & DEV (FR) | 2004-03-10 | — | — | EP | claimed |
| US-20030113281-A1 | Assay for identification of compounds that promote melanin production and retinoid-like compounds identified by said assay | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-06-19 | — | — | US | claimed |
| US-6391287-B1 | STORAGE STABLE COMPOSITIONS | L'OREAL (FR) | 2002-05-21 | — | — | US | claimed |
| EP-1082111-A1 | ASSAY FOR IDENTIFICATION OF COMPOUNDS THAT PROMOTE MELANIN PRODUCTION AND RETINOID-LIKE COMPOUNDS IDENTIFIED BY SAID ASSAY | Galderma Research & Development, S.N.C. (FR) | 2001-03-14 | — | — | EP | claimed |
| EP-1019049-A1 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM) USING SPECIFIC RETINOID COMPOUNDS | Galderma Research & Development, S.N.C. (FR) | 2000-07-19 | — | — | EP | claimed |
| US-6001885-A | INHIBITING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) EXPRESSION IN KERATINOCYTES BY ADMINISTERING AT LEAST ONE RETINOID; USEFUL FOR TREATING DISEASES RELATING TO VEGF OVEREXPRESSION, SUCH AS PSORIASIS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 1999-12-14 | — | — | US | claimed |
| WO-1999056740-A1 | ASSAY FOR IDENTIFICATION OF COMPOUNDS THAT PROMOTE MELANIN PRODUCTION AND RETINOID-LIKE COMPOUNDS IDENTIFIED BY SAID ASSAY | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-11-11 | — | — | WO | claimed |
| WO-1998042340-A9 | RETINOID RELATED MOLECULES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS | — | 1999-03-04 | — | — | WO | claimed |
| WO-1998042340-A1 | RETINOID RELATED MOLECULES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1998-10-01 | — | — | WO | claimed |
| US-5766610-A | USEFUL FOR TREATMENT OF MAMMALIAN SKIN AND HAIR, RHEUMATISM, RESIPIRATORY SYSTEM DISORDER, CARDIOVASCULAR AND VISION DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-06-16 | — | — | US | claimed |
| EP-0679630-B1 | Bicyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses | CIRD GALDERMA (FR) | 1998-05-06 | — | — | EP | claimed |
| WO-1997016422-A1 | SULFIDES, SULFOXIDES AND SULFONES DISUBSTITUTED WITH A TETRAHYDRONAPHTHALENYL, CHROMANYL, THIOCHROMANYL OR TETRAHYDROQUINOLINYL AND SUBSTITUTED PHENYL OR HETEROARYL GROUP, HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1997-05-09 | — | — | WO | claimed |
| US-20230312253-A1 | YEAST CELLS HAVING DISRUPTED PATHWAY FROM DIHYDROXYACETONE PHOSPHATE TO GLYCEROL | CARGILL, INCORPORATED (US) | 2023-10-05 | — | — | US | disclosed |
| US-11691817-B2 | Yeast cells having disrupted pathway from dihydroxyacetone phosphate to glycerol | CARGILL, INCORPORATED (US) | 2023-07-04 | — | — | US | disclosed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994015902-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234337-A1 | FOAMING COMPOSITIONS FOR HAIR CARE | RARA, NR5A1, SHH | RXRA 12/4885RXRB 20/4885RXRG 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.